ReviewAmylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity

Add time:08/26/2019    Source:sciencedirect.com

BackgroundAmylin is a pancreatic β-cell hormone that produces effects in several different organ systems. One of its best-characterized effects is the reduction in eating and body weight seen in preclinical and clinical studies. Amylin activates specific receptors, a portion of which it shares with calcitonin gene-related peptide (CGRP). Amylin's role in the control of energy metabolism relates to its satiating effect, but recent data indicate that amylin may also affect hedonic aspects in the control of eating, including a reduction of the rewarding value of food. Recently, several amylin-based peptides have been characterized. Pramlintide (Symlin®) is currently the only one being used clinically to treat type 1 and type 2 diabetes. However other amylin analogs with improved pharmacokinetic properties are being considered as anti-obesity treatment strategies. Several other studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents.

We also recommend Trading Suppliers and Manufacturers of AMYLIN (8-37) (RAT) (cas 138398-61-5). Pls Click Website Link as below: cas 138398-61-5 suppliers

Prev:Amylin and diabetic cardiomyopathy – amylin-induced sarcolemmal Ca2 + leak is independent of diabetic remodeling of myocardium☆
Next:Protein aggregates and proteostasis in aging: Amylin and β-cell function)